FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine

Morbidity and Mortality Weekly Report

Volumn 58, Issue 14, 2009, Pages 374-375

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CLINICAL TRIAL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CLINICAL TRIALS AS TOPIC; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG APPROVAL; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; MIDDLE AGED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 64749085743     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-3).
2. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR 2006;55(No. RR-17).
3. CDC. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57(No. RR-4).
4. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, March 15, 2005, briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097b1.htm.
5. Food and Drug Administration. Product approval information-licensing action. Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at http://www.fda.gov/cber/approvltr/tdapgla050305l.htm.
6. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37--41.
7. McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007;25:3464--74.
8. Halperin SA, Sweet L, Baxendale D, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J 2006;25:195--200.